Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose.

27 Mar 2014

2014 Biotech China to be held on 14-16 May in Nanjing, China

Biotech China, the first major Chinese biotech exhibition and conference, will hold the 2014 Biotech China on 14-16th May, 2014 in Nanjing, China.

27 Mar 2014

New era of lung cancer therapy close to dawning

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

27 Mar 2014

The Center for Applied Nanotechnology presents a ready-to-use reagent for the detection of poly-histidine tagged proteins in Blot assays

The nano-experts from the Center for Applied Nanotechnology (CAN) GmbH expand their product portfolio by CANdots® Series G - His Detect, which is a ready-to-use reagent for the detection of poly-histidine tagged proteins in Blot assays. It is easy to handle, highly sensitive as well as time saving compared to standard methods available on the market, e.g. ECL.

25 Mar 2014

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys Limited, a clinical stage biotechnology company, is pleased to provide an update on the development programme for anti-cancer product, PAT-LM1.

24 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Genzyme, a Sanofi company, announced today that Brazil's national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

21 Mar 2014

NIH awarded five-year grant of up to $28 million to fight deadly Ebola virus

The National Institutes of Health (NIH) has awarded a five-year grant of up to $28 million to establish a new center for excellence to find an antibody "cocktail" to fight the deadly Ebola virus.

21 Mar 2014

New treatment could halt progression of dementia

Researchers at the University of Texas Medical Branch at Galveston have discovered a way to potentially halt the progression of dementia caused by accumulation of a protein known as tau.

21 Mar 2014

NIH awards $28M grant to establish new center for excellence to find treatment for Ebola virus

The National Institutes of Health has awarded a five-year, $28 million grant to establish a new center for excellence to find an antibody "cocktail" to fight two types of viruses that cause severe hemorrhagic fever, including the deadly Ebola virus. The project involves researchers from 15 institutions, including Kartik Chandran, Ph.D., and Jonathan Lai, Ph.D., at Albert Einstein College of Medicine of Yeshiva University. Einstein will receive approximately $4 million of the total grant.

21 Mar 2014

Added benefit of ipilimumab in advanced melanoma not proven for non-pretreated patients

The German Institute for Quality and Efficiency in Health Care already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previous treatment. In the new dossier compiled by the drug manufacturer, the drug was now compared with the appropriate comparator therapy dacarbazine specified by the Federal Joint Committee (G-BA) also for non-pretreated patients.

19 Mar 2014

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).

19 Mar 2014

Chemical engineers design way to manufacture peptides in mere hours

Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018.

19 Mar 2014

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).

18 Mar 2014

ChromaTrap™ Chromatin Immunoprecipitation technology receives positive commentary in published paper

Porvair Sciences reports on positive commentary by researchers in published papers citing how using the fast, sensitive ChromaTrap™ Chromatin Immunoprecipitation (ChIP) technology has benefited their research.

From Chromatrap® - Porvair Sciences Ltd 18 Mar 2014

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.

14 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune response, ultimately allowing solid tumors to act as their own cancer-fighting vaccine.

13 Mar 2014

High antibody affinity identifies type 1 diabetes

LADA (latent autoimmune diabetes in adults) is a form of type 1 diabetes in adulthood. Like the childhood form, the insulin-producing beta cells of the pancreas are destroyed by the body's own immune system.

11 Mar 2014

Antibody News and Research

Further Reading

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

2014 Biotech China to be held on 14-16 May in Nanjing, China

New era of lung cancer therapy close to dawning

The Center for Applied Nanotechnology presents a ready-to-use reagent for the detection of poly-histidine tagged proteins in Blot assays

Patrys provides update on development programme for anti-cancer product, PAT-LM1

FDA approves Xolair for treatment of chronic idiopathic urticaria

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

NIH awarded five-year grant of up to $28 million to fight deadly Ebola virus

New treatment could halt progression of dementia

NIH awards $28M grant to establish new center for excellence to find treatment for Ebola virus

Added benefit of ipilimumab in advanced melanoma not proven for non-pretreated patients

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Chemical engineers design way to manufacture peptides in mere hours

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

ChromaTrap™ Chromatin Immunoprecipitation technology receives positive commentary in published paper

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

High antibody affinity identifies type 1 diabetes

Monoclonal Antibody Manufacturing Trends eBook eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News